| Publication date | System/disease context | Main finding about P4HA2 | Methods/evidence type | Quantitative details available | URL/DOI | PaperQA citation ID |
|---|---|---|---|---|---|---|
| Jun 2024 | Colorectal cancer (CRC) | P4HA2 is overexpressed in CRC, promotes proliferation, migration, and EMT, and is transcriptionally activated by SP1 binding to the P4HA2 promoter (pqac-00000007) | TCGA expression analysis; western blot on paired tumors; tissue microarray; ChIP; luciferase assays; in vitro and in vivo functional assays (pqac-00000007) | 18 paired tumor/normal specimens by western blot; tissue microarray of 349 CRC cases; no HR reported in gathered evidence (pqac-00000007) | https://doi.org/10.1080/15384047.2024.2361594 | (pqac-00000007) |
| Apr 2024 | Lung adenocarcinoma | P4HA2 directly binds mTOR and hydroxylates conserved mTOR Pro2341, increasing mTOR stability, substrate recognition, and kinase signaling to S6K and AKT; targeting the P4HA2-mTOR axis suppresses growth (pqac-00000008) | Mechanistic biochemistry; proteomic IP; GST pull-down; mutant analysis; cell growth assays; combination pharmacology (pqac-00000008) | mTOR residue P2341 identified as hydroxylation site; P4HA2 found among 634 potential mTOR-interacting proteins; mTORP2341A reduced A549 growth; no clinical HR in gathered evidence (pqac-00000008) | https://doi.org/10.1038/s41388-024-03032-1 | (pqac-00000008) |
| Jun 2024 | B-cell lymphoma / stromal Hedgehog signaling | P4HA2 forms a complex with KIF7, relocalizes to the primary cilium tip after Hedgehog activation, hydroxylates SUFU, inhibits SUFU function, and amplifies paracrine Hedgehog signaling to promote lymphoma progression (pqac-00000009) | Cell biology and signaling study in lymphoma/stromal context; mechanistic hydroxylation evidence (pqac-00000009) | Key substrate identified as SUFU; localization shift to ciliary tip noted; no sample size or HR reported in gathered evidence (pqac-00000009) | https://doi.org/10.1038/s41375-024-02313-8 | (pqac-00000009) |
| May 2024 | Head and neck squamous cell carcinoma (HNSCC) | P4HA2 is upregulated in HNSCC, enhances proliferation, migration, invasion, and EMT, reduces apoptosis, and acts through PI3K/AKT signaling; LY294002 reverses these effects (pqac-00000010) | Integrated bioinformatics; patient tissues; CAL-27 cell functional assays; western blot; pathway inhibition (pqac-00000010) | 36 HNSCC tissues collected 2019-2021; CAL-27, FaDu, HN4, and HOK cells used; no HR reported in gathered evidence (pqac-00000010) | https://doi.org/10.1007/s12032-024-02358-w | (pqac-00000010) |
| Jul 2024 | Oral squamous cell carcinoma (OSCC) | P4HA2 is overexpressed in OSCC, inversely correlates with survival, and promotes invasion, migration, proliferation, and metastasis through PI3K/AKT pathway activation (pqac-00000011) | Multi-database expression/prognosis analysis; knockdown/overexpression models; in vitro and in vivo assays (pqac-00000011) | Prognosis assessed using TCGA/TIMER/UALCAN/GEPIA/KM-plotter; no numerical HR or sample size reported in gathered evidence (pqac-00000011) | https://doi.org/10.1038/s41598-024-64264-5 | (pqac-00000011) |
| May 2024 | Head and neck cancer biomarker analysis | Family-level analysis found P4HA2 (with P4HA1) associated with tumor stage, prognosis, and immune infiltration in HNSC; supports P4HA2 as biomarker candidate (pqac-00000006) | Multi-database transcriptomic and survival/immunology analysis; biomarker study (pqac-00000006) | Reports significant overexpression of P4H1-3 in HNSC but no HR or cohort size captured in gathered evidence (pqac-00000006) | https://doi.org/10.1038/s41598-024-62678-9 | (pqac-00000006) |
| Mar 2024 | Osteosarcoma biomarker analysis | P4HA2 is elevated in osteosarcoma, associated with poorer overall survival, retained independent prognostic value, and linked by GSEA to MAPK, NK-cell cytotoxicity, and T-cell receptor pathways (pqac-00000003) | GEO-based transcriptomics; PCR validation; prognostic modeling; Cox regression; GSEA; HPA interrogation (pqac-00000003) | GEO datasets GSE16088 and GSE73166 used; independent prognostic value reported but no HR captured in gathered evidence (pqac-00000003) | https://doi.org/10.1016/j.heliyon.2024.e27191 | (pqac-00000003) |
| Jan 2024 | Hypoxia-ECM review | Review places P4HA2 in hypoxia-regulated ECM remodeling, noting P4HA1 and P4HA2 as genes encoding prolyl 4-hydroxylase alpha subunits involved in collagen hydroxylation under hypoxic control (pqac-00000002) | Narrative review of HIF-dependent extracellular-matrix regulation (pqac-00000002) | No original cohort size; provides pathway-level context rather than new quantitative P4HA2 statistics (pqac-00000002) | https://doi.org/10.32604/biocell.2024.048873 | (pqac-00000002) |


*Table: This table summarizes key 2023-2024 developments for human P4HA2, emphasizing mechanistic discoveries, cancer-related functions, and biomarker evidence. It is useful for quickly comparing where P4HA2 acts, what was shown experimentally, and what quantitative details are currently available.*